Blocking Respiratory Syncytial Virus Entry: A Story with Twists

DNA and Cell Biology

Volumn 34, Issue 8, 2015, Pages 505-510

  Weisshaar, Marco ^a   Cox, Robert ^a   Plemper, Richard K ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 1,3 DIHYDRO 3 [[1 (4 HYDROXYBUTYL) 1H BENZIMIDAZOL 2 YL]METHYL] 2H IMIDAZO[4,5 C]PYRIDIN 2 ONE; ALS 8176; ANTIVIRUS AGENT; ENFUVIRTIDE; GS 5806; NUCLEOSIDE DERIVATIVE; RNA DIRECTED RNA POLYMERASE INHIBITOR; TMC 353131; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; MOLECULAR LIBRARY;

ADAPTATION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; COMPETITIVE INHIBITION; CROSS RESISTANCE; DRUG BINDING SITE; DRUG MECHANISM; DRUG SCREENING; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; KINETICS; PRIORITY JOURNAL; THERMODYNAMICS; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN; ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; MOLECULAR LIBRARY; MOUSE; PHYSIOLOGY; PROCEDURES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ANIMALS; ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; HUMANS; MICE; MODELS, MOLECULAR; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SMALL MOLECULE LIBRARIES; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 84938343640     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2015.2896     Document Type: Article

References (39)

1. Anderson, L.J., Parker, R.A., and Strikas, R.L. (1990). Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis 161, 640-646.
2. Andries, K., Moeremans, M., Gevers, T., Willebrords, R., Sommen, C., Lacrampe, J., et al. (2003). Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res 60, 209-219.
3. Arkin, M.R., Tang, Y., and Wells, J.A. (2014). Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol 21, 1102-1114.
4. Bjornson, C.L., and Johnson, D.W. (2008). Croup. Lancet 371, 329-339.
5. Bose, S., Heath, C.M., Shah, P.A., Alayyoubi, M., Jardetzky, T.S., and Lamb, R.A. (2013). Mutations in the parainfluenza virus 5 fusion protein reveal domains important for fusion triggering and metastability. J Virol 87, 13520-13531.
6. Brindley, M.A., Plattet, P., and Plemper, R.K. (2014). Efficient replication of a paramyxovirus independent of full zippering of the fusion protein six-helix bundle domain. Proc Natl Acad Sci U S A 111, E3795-E3804.
7. Broor, S., Parveen, S., Bharaj, P., Prasad, V.S., Srinivasulu, K.N., Sumanth, K.M., et al. (2007). A prospective three-year cohort study of the epidemiology and virology of acute respiratory infections of children in rural India. PLoS One 2, e491.
8. Cianci, C., Yu, K.L., Combrink, K., Sin, N., Pearce, B., Wang, A., et al. (2004). Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 48, 413-422.
9. Collins, P.L., and Crowe, J.E., Jr. (2007). Respiratory syncytial virus and metapneumoviruses. In Fields Virology. D.M. Knipe, and P.M. Howley, eds. (Lippincott, Williams, &Wilkins, Philadelphia), pp. 1601-1645.
10. De Feo, C.J., Wang, W., Hsieh, M.L., Zhuang, M., Vassell, R., and Weiss, C.D. (2014). Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics. Retrovirology 11, 86.
11. Devincenzo, J., Fathi, H., Mcclure, M., Westland, C., Harrison, L., Symons, J., et al. (2014). Treatment with Oral ALS-008176, a Nucleoside Analog, Rapidly Reduces RSV Viral Load and Clinical Disease Severity in a Healthy Volunteer Challenge Study. Open Forum Infect Dis 1, S66-S69.
12. Douglas, J.L., Panis, M.L., Ho, E., Lin, K.Y., Krawczyk, S.H., Grant, D.M., et al. (2003). Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol 77, 5054-5064.
13. Douglas, J.L., Panis, M.L., Ho, E., Lin, K.Y., Krawczyk, S.H., Grant, D.M., et al. (2005). Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother 49, 2460-2466.
14. Doyle, J., Prussia, A., White, L.K., Sun, A., Liotta, D.C., Snyder, J.P., et al. (2006). Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol 80, 1524-1536.
15. Hall, C.B., Granoff, D.M., Gromisch, D.S., Halsey, N.A., Kohl, S., Marcuse, E.K., et al. (1993). Use of Ribavirin in the Treatment of Respiratory Syncytial Virus-Infection. Pediatrics 92, 501-504.
16. Hampp, C., Kauf, T.L., Saidi, A.S., and Winterstein, A.G. (2011). Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med 165, 498-505.
17. Hermann, F.G., Egerer, L., Brauer, F., Gerum, C., Schwalbe, H., Dietrich, U., et al. (2009). Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46. J Virol 83, 4844-4853.
18. Hotard, A.L., Lee, S., Currier, M.G., Crowe, J.E., Jr., Sakamoto, K., Newcomb, D.C., et al. (2015). Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis. J Virol 89, 512-522.
19. Johnson, D.W. (2009). Croup. BMJ Clin Evid 3, 321-361.
20. Kamal-Bahl, S., Doshi, J., Campbell, J. (2002). Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med 156, 1034-1041.
21. Lamb, R.A., and Parks, G.D. (2007). Paramyxoviridae: the viruses and their replication. In Fields Virology. D.M. Knipe and P.M. Howley, eds. (Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia), pp. 1449-1496.
22. Mackman, R.L., Sangi, M., Sperandio, D., Parrish, J.P., Eisenberg, E., Perron, M., et al. (2015). Discovery of an Oral Respiratory Syncytial Virus (RSV) Fusion Inhibitor (GS-5806) and Clinical Proof of Concept in a Human RSV Challenge Study. J Med Chem 58, 1630-1643.
23. Mahadevia, P.J., Makari, D., and Masaquel, A. (2012a). Methodological concerns regarding cost-effectiveness analysis of palivizumab in Florida Medicaid. Arch Pediatr Adolesc Med 166, 968-969; author reply 9-70.
24. Mahadevia, P.J., Masaquel, A.S., Polak, M.J., and Weiner, L.B. (2012b). Cost utility of palivizumab prophylaxis among preterm infants in the United States: a national policy perspective. J Med Econ 15, 987-996.
25. McKimm-Breschkin, J. (2000). VP-14637 ViroPharma. Curr Opin Invest Drugs 1, 425-427.
26. McLellan, J.S., Chen, M., Leung, S., Graepel, K.W., Du, X., Yang, Y., et al. (2013). Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117.
27. Mink, M., Mosier, S.M., Janumpalli, S., Davison, D., Jin, L., Melby, T., et al. (2005). Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 79, 12447-12454.
28. Nair, H., Nokes, D.J., Gessner, B.D., Dherani, M., Madhi, S.A., Singleton, R.J., et al. (2010). Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375, 1545-1555.
29. Razinkov, V., Gazumyan, A., Nikitenko, A., Ellestad, G., and Krishnamurthy, G. (2001). RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol 8, 645-659.
30. Reeves, J.D., Gallo, S.A., Ahmad, N., Miamidian, J.L., Harvey, P.E., Sharron, M., et al. (2002). Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 99, 16249-16254.
31. Roymans, D., De Bondt, H.L., Arnoult, E., Geluykens, P., Gevers, T., Van Ginderen, M., et al. (2010). Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A 107, 308-313.
32. Su, Y., Chong, H., Qiu, Z., Xiong, S., and He, Y. (2015). Mechanism of HIV-1 resistance to short peptide fusion inhibitors targeting the Gp41 pocket. J Virol [Epub ahead of print]; DOI: 10.1128/JVI.00373-15.
33. Wang, G., Deval, J., Hong, J., Dyatkina, N., Prhavc, M., Taylor, J., et al. (2015). Discovery of 4′-Chloromethyl-2′-deoxy-3′,5′- di-O-isobutyryl-2′-fluorocytidine (ALS-8176), A first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem 58, 1862-1878.
34. Weiner, L.B., Masaquel, A.S., Polak, M.J., and Mahadevia, P.J. (2012). Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. J Med Econ 15, 997-1018.
35. Wyde, P.R., Chetty, S.N., Timmerman, P., Gilbert, B.E., and Andries, K. (2003). Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antivir Res 60, 221-231.
36. Wyde, P.R., Moore-Poveda, D.K., O'Hara, B., Ding, W.D., Mitsner, B., and Gilbert, B.E. (1998). CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antivir Res 38, 31-42.
37. Yan, D., Lee, S., Thakkar, V.D., Luo, M., Moore, M.L., and Plemper, R.K. (2014). Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors. Proc Natl Acad Sci U S A. 111, E3441-E3449.
38. Yin, H.S., Wen, X., Paterson, R.G., Lamb, R.A., and Jardetzky, T.S. (2006). Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439, 38-44.
39. Yu, K.L., Zhang, Y., Civiello, R.L., Kadow, K.F., Cianci, C., Krystal, M., et al. (2003). Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor. Bioorg Med Chem Lett 13, 2141-2144.